Sort   by:  
 Page size 
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownRetrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.
Not available
S-EPMC7505971 | biostudies-literature
UnknownGenomic footprints of activated telomere maintenance mechanisms in cancer.
Not available
S-EPMC7002710 | biostudies-literature
UnknownCombined burden and functional impact tests for cancer driver discovery using DriverPower.
Not available
S-EPMC7002750 | biostudies-literature
UnknownCancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis.
Not available
S-EPMC7002399 | biostudies-literature
UnknownDisruption of chromatin folding domains by somatic genomic rearrangements in human cancer.
Not available
S-EPMC7058537 | biostudies-literature
UnknownHigh-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.
Not available
S-EPMC7002524 | biostudies-literature
UnknownPathway and network analysis of more than 2500 whole cancer genomes.
Not available
S-EPMC7002574 | biostudies-literature
Sort   by:  
 Page size